fbpx

News

19 08, 2022

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

2022-08-19T18:58:40+00:00August 19th, 2022|

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to [...]

12 07, 2022

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

2022-09-19T16:19:23+00:00July 12th, 2022|

EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). [...]

26 04, 2022

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

2022-09-19T16:20:04+00:00April 26th, 2022|

April 21, 2022 12:00 UTC TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company’s Phase 1/2a clinical trial of [...]

7 01, 2022

A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults

2022-01-07T20:35:12+00:00January 7th, 2022|

Pharmaceutical companies have used experimental models of transient insomnia to assess the sleep-promoting effects of investigational drugs for over 40 years.  These models have included the "first-night effect" model, a parallel-group design that assessed drug effects when sleep was recorded in normal, healthy subjects who slept in a new or novel environment for the [...]

7 06, 2021

Clinilabs Drug Development Corporation Joins Decentralized Trials & Research Alliance (DTRA) to Accelerate Clinical Trials

2021-06-08T16:27:28+00:00June 7th, 2021|

Clinilabs and the DTRA Aim to Dramatically Increase Access for All Patient Populations in Clinical Trials and Research June 7, 2021 – Clinilabs Drug Development Corporation joins a historic alliance of over one hundred life science and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized [...]

12 05, 2021

Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia

2021-05-24T20:04:46+00:00May 12th, 2021|

Clinilabs congratulates Larimar Therapeutics Inc. on their Topline Phase 1 Clinical Trial Data in patients with Friedreich’s Ataxia! We are proud to have been part of this clinical trial and to have worked with this partner who is dedicated to bringing life changing treatments to patients with this rare disease. To learn more about [...]

19 02, 2021

With a Pandemic Push, DCTs Are a ‘Virtual’ Lock to Go Big in ‘21

2021-02-22T20:14:00+00:00February 19th, 2021|

2020 will go down as a miserable year, but beyond the heartache, some developments may represent bright spots that light the way to the future. One of these is the growth of Decentralized Clinical Trials (DCTs). DCTs are virtual trials that integrate remote assessments with modern digital health technologies, including remote rating apps, wearable monitoring [...]

1 12, 2020

T3D Therapeutics selects Clinilabs Drug Development Corporation as contract research organization partner for Phase 2 trial of T3D-959 in patients with Alzheimer’s Disease.

2020-12-01T21:41:09+00:00December 1st, 2020|

T3D Therapeutics, Inc. (“T3D Therapeutics” or the “Company”), a biopharmaceutical company specializing in the development of ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease and other neurodegenerative diseases, announced it has engaged Clinilabs Drug Development Corporation (“Clinilabs”) as the contract research organization (“CRO”) for its upcoming phase 2 trial of T3D-959 named the PIONEER [...]

23 03, 2020

Webinar: COVID-19 | CNS Clinical Trial Contingency Plans for Sponsors and Investigator Sites

2020-12-01T21:12:30+00:00March 23rd, 2020|

We know how unsettling these times are for everyone - especially for those of us in the clinical trials space who need guidance on how to manage the demands of ongoing and future CNS clinical trials. Despite these challenges, we know now more than ever, the importance of the scientific community and the medical [...]

10 03, 2020

Supporting Our Patients and Research Subjects Amidst COVID-19 Concerns

2020-04-15T19:17:29+00:00March 10th, 2020|

By now, you have likely heard about the Coronavirus (officially called “2019-Novel Coronavirus” or “COVID-19”) in the news. While the immediate health risk remains low to Americans, there are still ways that all of us can play a role in helping to prevent the spread of this and other viruses. With that said, Clinilabs, the [...]